¼¼°èÀÇ Ç׹흰üÈ£¸£¸ó(AMH) °Ë»ç ½ÃÀå ±Ô¸ð Á¶»ç : Á¦Ç°º°, ÃÖÁ¾»ç¿ëÀÚº°, À¯Å뺰, ¿ëµµº°, Áö¿ªº° ¿¹Ãø(2022-2032³â)
Global Anti-Mullerian Hormone Test Market Size Study, by Product, by End-User, by Distribution, by Use, and Regional Forecasts 2022-2032
»óǰÄÚµå : 1517299
¸®¼­Ä¡»ç : Bizwit Research & Consulting LLP
¹ßÇàÀÏ : 2024³â 07¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 200 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,950 £Ü 6,989,000
Unprintable PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠺Ұ¡´ÉÇϸç, ÅØ½ºÆ®ÀÇ Copy&Pasteµµ ºÒ°¡´ÉÇÕ´Ï´Ù.
US $ 6,250 £Ü 8,825,000
Printable PDF (Enterprise License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

¼¼°è Ç׹흰üÈ£¸£¸ó(AMH) °Ë»ç ½ÃÀåÀº 2023³â ¾à 2¾ï 7,426¸¸ ´Þ·¯·Î Æò°¡µÇ¸ç, ¿¹Ãø ±â°£ÀÎ 2024³âºÎÅÍ 2032³â±îÁö 11.46% ÀÌ»óÀÇ °Ç°­ÇÑ ¼ºÀå·ü·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

AMH °Ë»ç´Â »ý½Ä ÀÇÇп¡¼­ Áß¿äÇÑ Áø´Ü µµ±¸·Î ³­¼Ò ¿¹ºñ·Â, ³­ÀÚÀÇ ¾ç, ÀáÀçÀû Àӽа¡´É¼º¿¡ ´ëÇÑ Áß¿äÇÑ Á¤º¸¸¦ Á¦°øÇÕ´Ï´Ù. ÀÌ °Ë»ç´Â ´Ù³¶¼º³­¼ÒÁõÈıº(PCOS), ¿ø¹ß¼º ³­¼Ò ±â´É ºÎÀü(POI) µîÀÇ »óŸ¦ Æò°¡ÇÏ´Â µ¥ ƯÈ÷ À¯¿ëÇϸç, ü¿Ü¼öÁ¤(IVF) °úÁ¤¿¡¼­ ¾à¹° Åõ¿© ¹× ³­¼Ò ¹ÝÀÀÀ» ¿¹ÃøÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. »ý½Ä °Ç°­ ¹®Á¦¿¡ ´ëÇÑ ÀνÄÀÇ Áõ°¡, Á¶±â ¹× Á¤È®ÇÑ ºÒÀÓ Áø´ÜÀÇ Çʿ伺, ù ÀӽŠ¿¬·ÉÀÇ Áõ°¡ µîÀÌ AMH °Ë»ç¿¡ ´ëÇÑ ¼ö¿ä¸¦ ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ±â¼ú ¹ßÀü°ú ÀÇ·á ÀÎÇÁ¶óÀÇ È®ÀåÀ¸·Î ÀÎÇØ Á¢±Ù¼º°ú ±¸¸Å ¿ëÀ̼ºÀÌ ´õ¿í Çâ»óµÇ°í ÀÖ½À´Ï´Ù. ±×·¯³ª ÀúÀÚ¿ø ȯ°æ¿¡¼­ÀÇ Á¦ÇÑµÈ Àνİú ³ôÀº °Ë»ç ºñ¿ë, Ç¥ÁØÈ­µÈ °Ë»ç ÇÁ·ÎÅäÄÝÀÇ Çʿ伺°ú ÇÔ²² ½ÃÀå ħÅõ¿¡ ¾î·Á¿òÀ» °Þ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, AMH ¼öÄ¡¿Í °ü·Ã °¡ÀÓ·Â ¿äÀÎÀ» ÇØ¼®Çϱâ À§ÇÑ ±â¼ú ÅëÇÕÀº Å« ¼ºÀå ±âȸ¸¦ Á¦°øÇÕ´Ï´Ù.

POC(Point-of-Care) °Ë»ç´Â ÀÓ»ó ÇöÀå¿¡¼­ ½Å¼ÓÇÑ ÀÇ»ç°áÁ¤À» °¡´ÉÇÏ°Ô Çϰí Áï°¢ÀûÀÎ °á°ú¸¦ ¾òÀ» ¼ö Àֱ⠶§¹®¿¡ Á¡Á¡ ´õ ¼±È£µÇ°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Å×½ºÆ®´Â »ç¿ë ÆíÀǼº°ú ºü¸¥ °á°ú¸¦ Á¦°øÇϵµ·Ï ¼³°èµÇ¾î ºÒÀÓ Æò°¡ÀÇ °£¼ÒÈ­°¡ ÇÊ¿äÇÑ ÀÇ·á ¼­ºñ½º Á¦°øÀÚ¿¡°Ô ÀÌ»óÀûÀÔ´Ï´Ù. ÀÚ°¡ °Ë»ç ŰƮ´Â ÇÁ¶óÀ̹ö½Ã¿Í Æí¸®ÇÔÀ» ¿øÇÏ´Â °³Àο¡°Ô ÀûÇÕÇϸç, Áý¿¡¼­ ºÒÀÓ °Ë»çÀÇ Ãʱ⠴ܰ踦 ¼öÇàÇÒ ¼ö ÀÖ½À´Ï´Ù. »ó¾÷¿ë ½ÇÇè½ÇÀº ÀÓ»óÀÇ¿Í Àü¹®°¡¿¡°Ô °í±Þ Áø´Ü µµ±¸¸¦ Á¦°øÇÏ¿© ´ë·® °Ë»çÀÇ È¿À²¼º°ú ½Å·Ú¼ºÀ» º¸ÀåÇÕ´Ï´Ù. ¿¬±¸ °³¹ß(R&D) ±â°üÀº ºÒÀÓ Ä¡·á ¹× »ý½Ä ÀÇÇÐ ¿¬±¸¸¦ ÁøÇàÇϱâ À§ÇØ °í°¨µµ °Ë»ç¸¦ ¿ä±¸Çϰí ÀÖ½À´Ï´Ù. À¯Åë °æ·Î°¡ ÁøÈ­Çϰí ÀÖÀ¸¸ç, Æí¸®ÇÔ°ú ÇÁ¶óÀ̹ö½Ã¸¦ ¿øÇÏ´Â ¼ÒºñÀÚµéÀº »ó¼¼ÇÑ Á¦Ç° Á¤º¸¿Í »ç¿ëÀÚ ¸®ºä¸¦ Á¦°øÇÏ´Â ¿Â¶óÀÎ Ç÷§ÆûÀ» ¼±È£Çϰí ÀÖ½À´Ï´Ù.

Àΰ£ÀÇ °æ¿ì, AMH °Ë»ç´Â ³­¼Ò ¿¹ºñ·Â°ú °¡ÀÓ·ÂÀ» Æò°¡ÇÏ´Â °Ë»ç·Î ºÒÀÓ Ä¡·á¿Í »ý½Ä °Ç°­ Æò°¡¿¡ ¸Å¿ì Áß¿äÇÕ´Ï´Ù. ºñÀΰ£ ¿µÀå·ù¿¡¼­´Â º¸È£ Ȱµ¿°ú ¹ø½Ä ÇÁ·Î±×·¥ °ü¸®¿¡ µµ¿òÀÌ µÇ¸ç, ¹ø½Ä °¡´É¼º¿¡ ´ëÇÑ ÀλçÀÌÆ®¸¦ Á¦°øÇÕ´Ï´Ù.

Ç׹흰üÈ£¸£¸ó(AMH) °Ë»ç ¼¼°è ½ÃÀå Á¶»ç¿¡¼­ °í·ÁµÈ ÁÖ¿ä Áö¿ªÀº ¾Æ½Ã¾ÆÅÂÆò¾ç, ºÏ¹Ì, À¯·´, ¶óƾ¾Æ¸Þ¸®Ä« ¹× ±âŸ Áö¿ªÀÔ´Ï´Ù. ¾Æ½Ã¾ÆÅÂÆò¾çÀº Ç׹흰üÈ£¸£¸ó(AMH) °Ë»ç ½ÃÀå¿¡¼­ ¼öÀÍ Ãø¸é¿¡¼­ ¿ìÀ§¸¦ Á¡Çϰí ÀÖ½À´Ï´Ù. ÀÌ Áö¿ªÀÇ ½ÃÀå ¼ºÀåÀº ÀÇ·áºñ ÁöÃâ Áõ°¡¿Í ÀÎ½Ä °³¼± µîÀÇ ¿äÀο¡ ±âÀÎÇÕ´Ï´Ù. ¶ÇÇÑ, ÀÌ Áö¿ªÀº ¼±ÁøÀûÀÎ ÀÇ·á ÀÎÇÁ¶ó¿Í ´ë±Ô¸ð R&D ÅõÀÚ·Î ½ÃÀåÀ» ¼±µµÇϰí ÀÖ½À´Ï´Ù. ÇÑÆí, À¯·´ ½ÃÀåÀº ÇコÄɾî ÀÎÇÁ¶ó¿Í Á¤Ã¥ °­È­¿¡ ÈûÀÔ¾î ¿¹Ãø ±â°£ µ¿¾È °¡Àå ºü¸¥ ¼Óµµ·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå Ç׹흰üÈ£¸£¸ó(AMH) °Ë»ç ¼¼°è ½ÃÀå ÁÖ¿ä ¿ä¾à

Á¦2Àå Ç׹흰üÈ£¸£¸ó(AMH) °Ë»ç ¼¼°è ½ÃÀå Á¤ÀÇ¿Í Á¶»ç °¡Á¤

Á¦3Àå Ç׹흰üÈ£¸£¸ó(AMH) °Ë»ç ¼¼°è ½ÃÀå ¿ªÇÐ

Á¦4Àå ¼¼°èÀÇ Ç׹흰üÈ£¸£¸ó(AMH) °Ë»ç ½ÃÀå, »ê¾÷ ºÐ¼®

Á¦5Àå Ç׹흰üÈ£¸£¸ó(AMH) °Ë»ç ¼¼°è ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø : Àå Á¦Ç°º°, 2022-2032³â

Á¦6Àå Ç׹흰üÈ£¸£¸ó(AMH) °Ë»ç ¼¼°è ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø : ÃÖÁ¾»ç¿ëÀÚº°, 2022-2032³â

Á¦7Àå Ç׹흰üÈ£¸£¸ó(AMH) °Ë»ç ¼¼°è ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø : À¯Å뺰, 2022-2032³â

Á¦8Àå Ç׹흰üÈ£¸£¸ó(AMH) °Ë»ç ¼¼°è ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø : ¿ëµµº°, 2022-2032³â

Á¦9Àå Ç׹흰üÈ£¸£¸ó(AMH) °Ë»ç ¼¼°è ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø : Áö¿ªº°, 2022-2032³â

Á¦10Àå °æÀï Á¤º¸

Á¦11Àå Á¶»ç °úÁ¤

ksm
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Anti-Mullerian Hormone (AMH) Test Market is valued at approximately USD 274.26 million in 2023 and is anticipated to grow with a healthy growth rate of more than 11.46% over the forecast period 2024-2032. AMH tests are crucial diagnostic tools in reproductive medicine, providing essential information about ovarian reserve, egg quantity, and potential fertility. These tests are particularly valuable in assessing conditions such as polycystic ovary syndrome (PCOS) and primary ovarian insufficiency (POI) and are instrumental in in vitro fertilization (IVF) procedures for medication dosing and predicting ovarian response. The growing awareness of reproductive health issues, the necessity for early and precise fertility diagnosis, and the increasing age of first-time pregnancies drive the demand for AMH tests. Technological advancements and expanding healthcare infrastructure further enhance accessibility and affordability. However, the limited awareness in low-resource settings and the high cost of tests, coupled with the need for standardized testing protocols, present challenges to market penetration. Moreover, technological integration for interpreting AMH levels and related fertility factors offers significant growth opportunities.

Point-of-care (POC) testing is increasingly preferred for its immediate results, enabling swift decision-making in clinical practice. These tests are designed for ease of use and rapid results, ideal for healthcare providers needing to streamline fertility evaluations. Self-check kits cater to individuals seeking privacy and convenience, providing an initial step in fertility investigation from home. Commercial labs serve clinicians and specialists with advanced diagnostic tools, ensuring efficiency and reliability for high-volume testing. Research and development (R&D) institutions demand high-sensitivity tests for advancing fertility and reproductive health research. The distribution channels are evolving, with a growing preference for online platforms that offer detailed product information and user reviews, catering to consumers seeking convenience and privacy.

In humans, AMH tests assess ovarian reserve and fertility potential, crucial for fertility treatments and reproductive health evaluations. In non-human primates, these tests assist in conservation efforts and breeding program management, providing insights into reproductive potential.

The key regions considered for the global Anti-Mullerian Hormone (AMH) Test Market study include Asia Pacific, North America, Europe, Latin America, and Rest of the World. Asia-Pacific is a dominating region in the Anti-Mullerian Hormone (AMH) Test Market in terms of revenue. The market growth in the region is being attributed to factors including increasing healthcare expenditures and awareness. Also, the region lead with advanced healthcare infrastructure and significant R&D investments. Whereas, the market in Europe is anticipated to grow at the fastest rate over the forecast period fueled by enhancing healthcare infrastructures and policies.

Major market players included in this report are:

The detailed segments and sub-segment of the market are explained below:

By Product:

By End-User:

By Distribution:

By Use:

By Region:

North America:

Europe:

Asia Pacific:

Latin America:

Middle East & Africa:

Years considered for the study are as follows:

Key Takeaways:

Table of Contents

Chapter 1. Global Anti-Mullerian Hormone (AMH) Test Market Executive Summary

Chapter 2. Global Anti-Mullerian Hormone (AMH) Test Market Definition and Research Assumptions

Chapter 3. Global Anti-Mullerian Hormone (AMH) Test Market Dynamics

Chapter 4. Global Anti-Mullerian Hormone (AMH) Test Market Industry Analysis

Chapter 5. Global Anti-Mullerian Hormone (AMH) Test Market Size & Forecasts by Product 2022-2032

Chapter 6. Global Anti-Mullerian Hormone (AMH) Test Market Size & Forecasts by End-User 2022-2032

Chapter 7. Global Anti-Mullerian Hormone (AMH) Test Market Size & Forecasts by Distribution 2022-2032

Chapter 8. Global Anti-Mullerian Hormone (AMH) Test Market Size & Forecasts by Use 2022-2032

Chapter 9. Global Anti-Mullerian Hormone (AMH) Test Market Size & Forecasts by Region 2022-2032

Chapter 10. Competitive Intelligence

Chapter 11. Research Process

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â